Light and electron microscopic studies in a case of nasal glioma revealed a tumor composed nearly entirely of astrocytes. No ganglion cells or neurons were present and the mass was not surrounded by a capsule reminiscent for meningeal tissue. The vasculature resembled dermal patterns rather than typical central nervous system. No bone defect or connection to endocerebral tissue could be detected in the present case. Nasal glioma represents an ectopic focus of astrocytes, comparable to a hamartoma, rather than a true tumor or a herniation of brain tissue.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-4362.1982.tb02076.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nose-to-Brain Delivery of Biomimetic Nanoparticles for Glioblastoma Targeted Therapy.
ACS Appl Mater Interfaces
January 2025
Nanomedicine and Nanotoxicology Group, Physics Institute of São Carlos, São Paulo University, Avenida Trabalhador São Carlense, 400, São Carlos, SP 13560-970, Brazil.
Glioblastoma (GBM) is an extremely aggressive form of brain cancer that remains challenging to treat, especially owing to the lack of effective targeting and drug delivery concerns. Due to its anatomical advantages, the nose-to-brain strategy is an interesting route for drug delivery. Nanoengineering has provided technological tools and innovative strategies to overcome biotechnological limitations, which is promising for improving the effectiveness of conventional therapies.
View Article and Find Full Text PDFBacterial and bacterial derivatives-based drug delivery systems: a novel approach for treating central nervous system disorders.
Expert Opin Drug Deliv
December 2024
Department of Biopharmacy, School of Pharmaceutical Sciences, Jilin University, Changchun, PR China.
Introduction: Bacteria and their derivatives show great potential as drug delivery systems due to their unique chemotaxis, biocompatibility, and targeting abilities. In CNS disease treatment, bacterial carriers can cross the blood-brain barrier (BBB) and deliver drugs precisely, overcoming limitations of traditional methods. Advances in genetic engineering, synthetic biology, and nanotechnology have transformed these systems into multifunctional platforms for personalized CNS treatment.
View Article and Find Full Text PDFNasal Dermoid - A Series of Ten Cases and Review of Literature.
Indian J Otolaryngol Head Neck Surg
December 2024
Department of ENT, Chacha Nehru Bal Chikitsalya, Geeta Colony, New Delhi, India.
Congenital nasal swellings are commonly encountered in pediatric practice. Differential diagnosis includes dermoid cyst, meningoencephalocele, glioma, benign tumors. Here we discuss 10 cases of nasal dermoid which were studied between January 2022 - December 2022 to obtain clinical data for diagnosis and treatment in pediatric population.
View Article and Find Full Text PDFNeuropathology Entities Involving the Sinonasal Tract.
Surg Pathol Clin
December 2024
Department of Pathology & Immunology, Division of Neuropathology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA. Electronic address:
Article Synopsis
- Neuropathologic entities, though rare, can affect the sinonasal tract through different mechanisms including embryological defects and ectopic tissue remnants.
- These entities may also arise from benign tumors that extend from the brain or nearby structures, such as pituitary adenomas and meningiomas.
- Additionally, high-grade intracranial tumors like glioblastomas can invade the sinonasal area, making it essential for surgical pathologists to include these in the differential diagnoses of unusual sinonasal lesions.
A promise of nose to brain delivery of bevacizumab intranasal sol-gel formulation substantiated in rat C6 glioma model.
Naunyn Schmiedebergs Arch Pharmacol
October 2024
Department of Pharmacology, Bombay College of Pharmacy, Santacruz East, Mumbai, 400098, India.
Glioblastoma is one of the rapidly spreading cancers, with its potent malignancy often linked to pronounced angiogenesis within tumors. To mitigate this vascularization profile, bevacizumab (Avastin®), a monoclonal antibody, has been utilized for its antiangiogenic activity. However, its effectiveness is hindered by challenges in crossing the blood-brain barrier and the risk of off-target organ toxicity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!